177 related articles for article (PubMed ID: 36543869)
1. Part one: abuse liability of Vuse Solo (G2) electronic nicotine delivery system relative to combustible cigarettes and nicotine gum.
Campbell C; Jin T; Round EK; Schmidt E; Nelson P; Baxter S
Sci Rep; 2022 Dec; 12(1):22080. PubMed ID: 36543869
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum.
Stiles MF; Campbell LR; Jin T; Graff DW; Fant RV; Henningfield JE
Psychopharmacology (Berl); 2018 Jul; 235(7):2077-2086. PubMed ID: 29725702
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability.
Stiles MF; Campbell LR; Graff DW; Jones BA; Fant RV; Henningfield JE
Psychopharmacology (Berl); 2017 Sep; 234(17):2643-2655. PubMed ID: 28634710
[TBL] [Abstract][Full Text] [Related]
4. Abuse liability of two electronic nicotine delivery systems compared with combustible cigarettes and nicotine gum from an open-label randomized crossover study.
Campbell C; Jin T; Round EK; Nelson PR; Baxter S
Sci Rep; 2023 Nov; 13(1):18951. PubMed ID: 37919490
[TBL] [Abstract][Full Text] [Related]
5. Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers.
Goldenson NI; Buchhalter AR; Augustson EM; Rubinstein ML; Henningfield JE
Drug Alcohol Depend; 2020 Dec; 217():108395. PubMed ID: 33176942
[TBL] [Abstract][Full Text] [Related]
6. Abuse liability assessment of the JUUL system in two nicotine concentrations compared to combustible cigarette, nicotine gum and comparator electronic nicotine delivery system.
Goldenson NI; Buchhalter AR; Augustson EM; Rubinstein ML; Van Hoof D; Henningfield JE
Drug Alcohol Depend; 2020 Dec; 217():108441. PubMed ID: 33250386
[TBL] [Abstract][Full Text] [Related]
7. Assessment of abuse liability and switching potential of menthol-flavored pod-based electronic nicotine delivery systems among US adults who smoke cigarettes.
Goldenson NI; Shiffman S; Sembower MA; Black RA
Drug Alcohol Depend; 2024 May; 258():111279. PubMed ID: 38614020
[TBL] [Abstract][Full Text] [Related]
8. An abuse liability assessment of the glo tobacco heating product in comparison to combustible cigarettes and nicotine replacement therapy.
Hardie G; Gale N; McEwan M; Oscar SM; Ziviani L; Proctor CJ; Murphy J
Sci Rep; 2022 Aug; 12(1):14701. PubMed ID: 36038580
[TBL] [Abstract][Full Text] [Related]
9. Part three: a randomized study to assess biomarker changes in cigarette smokers switched to Vuse Solo or Abstinence.
Kanobe MN; Jones BA; Nelson P; Brown BG; Chen P; Makena P; Schmidt E; Darnell J; Caraway JW; Prasad GL; Nordskog B; Round EK
Sci Rep; 2022 Nov; 12(1):20658. PubMed ID: 36450821
[TBL] [Abstract][Full Text] [Related]
10. An Open-Label, Randomized, Controlled, Crossover Study to Assess Nicotine Pharmacokinetics and Subjective Effects of the JUUL System with Three Nicotine Concentrations Relative to Combustible Cigarettes in Adult Smokers.
Goldenson NI; Fearon IM; Buchhalter AR; Henningfield JE
Nicotine Tob Res; 2021 May; 23(6):947-955. PubMed ID: 33486526
[TBL] [Abstract][Full Text] [Related]
11. Comparison of design characteristics and toxicant emissions from Vuse Solo and Alto electronic nicotine delivery systems.
Talih S; Karaoghlanian N; Salman R; Fallah S; Helal A; El-Hage R; Saliba N; Breland A; Eissenberg T; Shihadeh A
Tob Control; 2023 Apr; ():. PubMed ID: 37072168
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum.
Round EK; Chen P; Taylor AK; Schmidt E
Nicotine Tob Res; 2019 Aug; 21(9):1239-1247. PubMed ID: 30202883
[TBL] [Abstract][Full Text] [Related]
13. Part two: an unblinded, parallel, randomized study to assess nicotine pharmacokinetics of four Vuse Solo ENDS flavors in smokers.
Keyser BM; Hong KS; DeLuca P; Jin T; Jones BA; Nelson P; Schmidt E; Round EK
Sci Rep; 2023 Jun; 13(1):8894. PubMed ID: 37264061
[TBL] [Abstract][Full Text] [Related]
14. Vuse Solo e-cigarettes do not provide net benefits to public health: a scientific analysis of FDA's marketing authorisation.
Glantz S; Lempert LK
Tob Control; 2024 Mar; 33(e1):e108-e115. PubMed ID: 36764683
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the Abuse Potential in Adult Smokers of a Novel Oral Tobacco Product Relative to Combustible Cigarettes and Nicotine Polacrilex Gum.
Liu J; Wang J; Vansickel A; Edmiston J; Graff D; Sarkar M
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):241-250. PubMed ID: 33502815
[TBL] [Abstract][Full Text] [Related]
16. A randomised, crossover, clinical study to assess nicotine pharmacokinetics and subjective effects of the BIDI
Fearon IM; Gilligan K; Seltzer RGN; McKinney W
Harm Reduct J; 2022 Jun; 19(1):57. PubMed ID: 35655314
[TBL] [Abstract][Full Text] [Related]
17. Nicotine delivery, tolerability and reduction of smoking urge in smokers following short-term use of one brand of electronic cigarettes.
D'Ruiz CD; Graff DW; Yan XS
BMC Public Health; 2015 Sep; 15():991. PubMed ID: 26424091
[TBL] [Abstract][Full Text] [Related]
18. Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation and third-generation electronic cigarette users.
Wagener TL; Floyd EL; Stepanov I; Driskill LM; Frank SG; Meier E; Leavens EL; Tackett AP; Molina N; Queimado L
Tob Control; 2017 Mar; 26(e1):e23-e28. PubMed ID: 27729564
[TBL] [Abstract][Full Text] [Related]
19. Human abuse liability assessment of e-cigarettes: Why, what and how?
Fearon IM
Drug Test Anal; 2023 Oct; 15(10):1211-1221. PubMed ID: 35302289
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and subjective assessment of prototype JUUL2 electronic nicotine delivery system in two nicotine concentrations, JUUL system, IQOS, and combustible cigarette.
Goldenson NI; Augustson EM; Chen J; Shiffman S
Psychopharmacology (Berl); 2022 Mar; 239(3):977-988. PubMed ID: 35184228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
